Neoadjuvant PD-1 Blockade in Resectable Lung Cancer; Nivolumab and Ipilimumab in Advanced Melanoma; Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma; Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy; Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma; Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma; Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma; Rapid

Abstract

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer (N Engl J Med 2018;378:1976-1986), Nivolumab and Ipilimumab in Advanced Melanoma (N Engl J Med 2017;377:2503-2504), Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma (N Engl J Med 2017;377:1345-1356), Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy (N Engl J Med 2016;375:1845-1855), Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma (N Engl J Med 2015;373:1270-1271), Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma (N Engl J Med 2015;373:23-34), Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma (N Engl J Med 2015;372:2006-2017), Rapid Eradication of a Bulky Melanoma Mass with One Dose of Immunotherapy (N Engl J Med 2015;372:2073-2074), Genetic Basis for Clinical Response to CTLA-4 Blockade (N Engl J Med 2015;372:783-783), Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma (N Engl J Med 2014;371:2189-2199), Nivolumab plus Ipilimumab in Advanced Melanoma (N Engl J Med 2013;369:122-133), Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma (N Engl J Med 2013;369:134-144), Hepatotoxicity with Combination of Vemurafenib and Ipilimumab (N Engl J Med 2013;368:1365-1366). Dr. Jedd D. Wolchok’s disclosures have been updated, and the articles are correct at NEJM.org. .